


# GSK FY 2019 results



GSK delivers a good performance with sales and earnings growth and strong cash generation

All % growth at constant exchange rates (CER)



Total EPS

**93.9p**

+23%

Adjusted EPS

**123.9p**

+1%

Free cash flow

**£5.1bn**

2019 dividend

**80p**


See **press release** on [www.gsk.com](http://www.gsk.com) for full details on FY 2019.

Please read the cautionary statement regarding the definitions and reconciliations for non-IFRS measures and the **forward-looking statements** on pages 9, 10, 21, 22, 59 and 60 of the press release.

CER% represents growth at constant exchange rates. For a full explanation please see page 60 of the press release.

\*Pro-forma growth +2%

\*\*Pro-forma growth +4%



Antibody with toxin attached